322 related articles for article (PubMed ID: 19744739)
1. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
[TBL] [Abstract][Full Text] [Related]
2. A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.
Fujioka T; Honda M; Yoshizaki T; Ogawa M; Matsuno H; Shimokawa K; Koyama K
Intern Med; 2010; 49(18):1987-90. PubMed ID: 20847504
[TBL] [Abstract][Full Text] [Related]
3. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
[No Abstract] [Full Text] [Related]
4. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C].
Lee YN; Jeong SW; Lim JH; Ryu YS; Jeon SR; Kim SK; Jang JY; Kim YS; Kim BS; Roh MO
Korean J Hepatol; 2010 Jun; 16(2):187-91. PubMed ID: 20606504
[TBL] [Abstract][Full Text] [Related]
5. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
6. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
[TBL] [Abstract][Full Text] [Related]
7. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
8. [Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C].
Primo Vera J
Gastroenterol Hepatol; 2004 Feb; 27(2):69. PubMed ID: 14733882
[No Abstract] [Full Text] [Related]
9. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Rogers CJ; Romagosa R; Vincek V
J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
[No Abstract] [Full Text] [Related]
10. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
11. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
Bhatti A; McGarrity TJ; Gabbay R
Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722
[No Abstract] [Full Text] [Related]
12. Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
Popescu C; Popescu GA; Arama V
J Gastrointestin Liver Dis; 2013 Mar; 22(1):101-4. PubMed ID: 23539399
[TBL] [Abstract][Full Text] [Related]
13. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
14. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
15. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
[No Abstract] [Full Text] [Related]
16. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
[TBL] [Abstract][Full Text] [Related]
17. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus.
Yagyu H; Okada K; Sato S; Yamashita Y; Okada N; Osuga J; Nagasaka S; Sugano K; Ishibashi S
Diabetes Res Clin Pract; 2012 Mar; 95(3):e52-4. PubMed ID: 22154462
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
20. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
